The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes

1. Age 18-75 years;

2. BMI≥25 kg/m²;

3. Diagnosed as type 2 diabetes mellitus patients according to the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)";

4. HbA1c≤8.5%;

5. Duration of diabetes ≤3 months, and no use of antihyperglycemic drugs;

6. Willing to participate in this study, and after full informed consent, agrees to strictly follow the treatment plan and promises to attend follow-up visits on time, and signs the informed consent form.

1. BMI < 25 kg/m²;

2. Age < 18 years, or > 75 years;

3. History of type 1 diabetes, acute pancreatitis, or diabetes secondary to pancreatectomy;

4. History of bariatric surgery or planned bariatric surgery, or currently attempting weight loss within the past 3 months, or use of weight-loss medications within the past 3 months;

5. Use of GLP-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, or other related drugs within the past 3 months;

6. Pregnant or breastfeeding women, or those planning to conceive during the study period;

7. Patients with severe diseases of important organ systems, such as severe cardiovascular and cerebrovascular diseases, respiratory diseases, gastrointestinal diseases, renal insufficiency, hematologic diseases, neurological diseases, or malignancies;

8. Personal or family history of medullary thyroid carcinoma;

9. Patients with severe mental disorders or communication barriers that prevent accurate understanding of the study content and compliance with the trial procedures.